Executive function in schizophrenia: what impact do antipsychotics have?
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Cognitive dysfunction is a major component of schizophrenia, with deficits in executive function particularly pertinent to successful daily living and outcome. Executive deficits and negative/disorganised symptoms remain relatively resistant to amelioration by antipsychotic medication in comparison to positive symptoms. While there is a relative paucity of data on the effects of antipsychotics on specific executive deficits, atypical antipsychotics would appear to be more beneficial than typical antipsychotics at improving these functions, with muscarinic, glutamatergic and cholinergic systems variously implicated. Recent research focusing on the relationships between specific symptoms and specific executive deficits holds important implications for future psychopharmacological interventions in the area by elucidating the neural substrates and pathways which underpin schizophrenic symptomatology. This review attempts to evaluate the research thus far for the specific executive components of spatial working memory (SWM), inhibition, sustained attention and set shifting. Issues significant to future psychopharmacology in the area are discussed, with particular emphasis on the need for a greater consensus in methodology and definition executive function research in schizophrenia. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Grant, D. A., & Berg, E. (1948) · Journal of Experimental Psychology · doi:10.1037/h0059831 · Cited by 2,244
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
On the ability to inhibit simple and choice reaction time responses: A model and a method.
Logan, G. D., Cowan, W. B., & Davis, K. A. (1984) · Journal of Experimental Psychology: Human Perception and Performance · doi:10.1037/0096-1523.10.2.276 · Cited by 1,542
The cognitive neuroscience of sustained attention: where top-down meets bottom-up.
Sarter, M., Givens, B., & Bruno, J. P. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00044-3 · Cited by 1,194 · cited 2×
“…agents' effects on executive function, cholinesterase inhibitors have been shown to improve performance in areas such as planning and sustained attention (Stip et al., 2004), the latter an important fundamental area for the successful execution of all cognitive functions (Sarter et al., 2001).”
Behavioural Assessment of the Dysexecutive Syndrome
(2004) · Methodology Of Frontal And Executive Function · doi:10.4324/9780203344187-15 · Cited by 1,149
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919 · cited 6×
“As such, evidence of psychopharmacological amelioration of cognitive deficits in schizophrenia thus far remains disparate and indeed two of the main issues impeding the development of new pharmacological agents aimed at improving executive function in schizophrenia are the determination of which approaches are most pr…”
InfluentialCornblatt, B. A., Risch, N. J., Faris, G., Friedman, D., & Erlenmeyer-Kimling, L. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90076-5 · Cited by 682
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544 · cited 1×
“Goldman-Rakic et al. (2004) implicate prefrontal dopamine (D 1 ) receptor activity or dysregulated signalling pathways in working memory deficits and highlight that hypodopaminergia in the PFC may underlie negative symptoms.”
Cited by
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
MacKillop, J., & Tidey, J. W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2185-8 · Cited by 154
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74
Ekman (1993) · doi:10.1016/j.neuropsychologia.2009.11.023 · Cited by 68
Metadata
- Authors
- O'Grada, C., & Dinan, T.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2007-06-20
- Volume
- 22
- Issue
- 6
- Pages
- 397-406
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1965492946
- Cited by
- 48
- References
- 16
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.